In order to strengthen and expand the R&D pipeline of anti-tumor drugs and accelerate the commercialization of products, it has become common
for pharmaceutical companies to join forces in this field in recent years.
Since 2022, a large number of domestic and foreign pharmaceutical companies have initiated cooperation
.
On November 6, AstraZeneca and Dunfu Medical Group held a strategic cooperation award ceremony at the AstraZeneca booth at the CIIE, and the two sides will carry out a number of innovative cooperation
in the field of medicine and health based on their respective advantages in platform and resources.
Among them, it is worth noting that the two parties will also work together to accelerate the landing and application
of new anti-tumor drugs in China.
Through this collaboration, DHF Medical will become a strategic partner
of AstraZeneca's innovative antibody conjugate drug (ADC).
AstraZeneca and Dunfu Medical will further accelerate the landing and application of innovative drugs in China, jointly promote the model of oncology special drug management services, and provide innovative patient service solutions.
On the same day, at the 5th China International Import Expo, Ranshi Medical and Eli Lilly reached a cooperative intention
in companion diagnosis.
The two parties will integrate the superior resources of all parties in the field of tumor diagnosis and treatment, focus on the management needs of patients throughout the course of the disease, jointly promote the popularization of innovative oncology drugs, and promote the new development of
precision diagnosis and treatment of cancer in China.
It is understood that this R&D cooperation focuses on the highly selective RET inhibitor ceplitinib that has been approved in the field of lung cancer and thyroid cancer in China, and jointly develops and commercializes ceptinib companion diagnostic reagents in China to detect RET gene mutations in lung cancer and thyroid cancer patients, so as to benefit more RET-driven cancer patients
in China.
On August 5, Innovent announced that it had reached a multi-project strategic cooperation and licensing agreement with Sanofi to cooperate in the development of two high-potential anti-tumor drugs SAR408701 (Tusamitamab Ravtansine; Anti-CEACAM5 antibody - drug conjugate) and SAR444245 (non-α biased IL-2) clinical development and commercialization in China, including a series of clinical studies exploring the combination of PD-1 inhibitor Daboshu ® (sindilimab injection), aiming to accelerate the development and market access of innovative therapies for the benefit of cancer patients
in China.
In May, Kelun Pharmaceutical said that its holding subsidiary, Kelun Botai, had licensed its biomacromolecular oncology project A (SKB264), with independent intellectual property rights, to MSD for research, development, manufacturing and commercialization
outside China (including Chinese mainland, Hong Kong, Macau and Taiwan).
.
.
.
.
.
.
Industry analysts believe that tumor treatment is one of the key areas of China's medical and health development, and there are a large number of unmet treatment needs
.
In the future, as enterprises continue to accelerate the research and development and application of new anti-tumor drugs through cooperation, they will better focus on unmet clinical needs and benefit the majority of patients
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
